PL2200

PLx Pharma · Phase 2 active Small molecule

At a glance

Generic name	PL2200
Also known as	PL-ASA
Sponsor	PLx Pharma
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects (PHASE2)
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients (PHASE3)
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients (PHASE3)
Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers (PHASE1, PHASE2)
Food-Effect Pharmacokinetic Study of PL2200 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PL2200 CI brief — competitive landscape report
PL2200 updates RSS · CI watch RSS
PLx Pharma portfolio CI